NCT06653842 - A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Cutaneous Venous Malformations

Interventions

DRUG

QTORIN 3.9% rapamycin anhydrous gel

QTORIN 3.9% Rapamycin Anhydrous Gel

Trial Locations (10)

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

RECRUITING

Johns Hopkins, Baltimore

RECRUITING

University of North Carolina, Chapel Hill

RECRUITING

Cleveland Clinic, Cleveland

RECRUITING

Minnesota Clinical Study Center, New Brighton

RECRUITING

Mayo Clinic, Rochester

RECRUITING

Colorado Children's Hospital, Aurora

RECRUITING

University of Utah Health, Salt Lake City

RECRUITING

Children's Hospital of Orange County, Irvine

RECRUITING

Stanford University, Palo Alto